These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 28207495)

  • 1. Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
    Myasoedova E
    Curr Opin Rheumatol; 2017 May; 29(3):277-284. PubMed ID: 28207495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis.
    Naerr GW; Rein P; Saely CH; Drexel H
    Vascul Pharmacol; 2016 Jun; 81():22-30. PubMed ID: 26903239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience.
    Schimmel EK; Yazici Y
    Clin Exp Rheumatol; 2009; 27(3):446-51. PubMed ID: 19604437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
    Kang EH; Liao KP; Kim SC
    Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Hollan I; Ronda N; Dessein P; Agewall S; Karpouzas G; Tamargo J; Niessner A; Savarese G; Rosano G; Kaski JC; Wassmann S; Meroni PL
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):104-114. PubMed ID: 31397840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?
    Day AL; Singh JA
    Drugs Aging; 2019 Jun; 36(6):493-510. PubMed ID: 30953327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment.
    Choy E; Ganeshalingam K; Semb AG; Szekanecz Z; Nurmohamed M
    Rheumatology (Oxford); 2014 Dec; 53(12):2143-54. PubMed ID: 24907149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids in RA: Is Less Not Necessarily More?
    Plutzky J; Liao KP
    Curr Rheumatol Rep; 2018 Feb; 20(2):8. PubMed ID: 29464513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk in rheumatoid arthritis.
    Nurmohamed MT
    Autoimmun Rev; 2009 Jul; 8(8):663-7. PubMed ID: 19393192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
    Charles-Schoeman C; Gonzalez-Gay MA; Kaplan I; Boy M; Geier J; Luo Z; Zuckerman A; Riese R
    Semin Arthritis Rheum; 2016 Aug; 46(1):71-80. PubMed ID: 27079757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review.
    Giollo A; Bissell LA; Buch MH
    Expert Opin Drug Saf; 2018 Jul; 17(7):697-708. PubMed ID: 29871535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.
    Barbhaiya M; Solomon DH
    Curr Opin Rheumatol; 2013 May; 25(3):317-24. PubMed ID: 23466960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.
    Amezaga Urruela M; Suarez-Almazor ME
    Curr Rheumatol Rep; 2012 Oct; 14(5):428-37. PubMed ID: 22802154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis.
    Nurmohamed MT
    Vasc Health Risk Manag; 2007; 3(6):845-52. PubMed ID: 18200805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm.
    Robertson J; Peters MJ; McInnes IB; Sattar N
    Nat Rev Rheumatol; 2013 Sep; 9(9):513-23. PubMed ID: 23774906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis.
    García-Gómez C; Nolla JM; Valverde J; Gómez-Gerique JA; Castro MJ; Pintó X
    J Rheumatol; 2009 Jul; 36(7):1365-70. PubMed ID: 19369465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment.
    Steiner G; Urowitz MB
    Semin Arthritis Rheum; 2009 Apr; 38(5):372-81. PubMed ID: 18395771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular safety of biologic therapies for the treatment of RA.
    Greenberg JD; Furer V; Farkouh ME
    Nat Rev Rheumatol; 2011 Nov; 8(1):13-21. PubMed ID: 22083220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.